文献速递胸部肿瘤放疗

首次立体定向体部放疗后局部复发的非小细胞肺癌与肺转移瘤的再次立体定向体部放疗

Repeat stereotactic body radiotherapy (SBRT) for local recurrence of non-small cell lung cancer and lung metastasis after first SBRT.
PubMed 文献 · Radiat Oncol · 2018-07-28

本研究评价再次立体定向体部放疗(SBRT)治疗Ⅰ期非小细胞肺癌(NSCLC)及孤立性肺转移瘤野内局部复发的安全性和疗效。31例患者(NSCLC 23例、肺转移瘤8例)接受再次SBRT,3年总生存率和局部控制率分别为36%和53%,第二次SBRT后放射性肺炎2级4例、未见3级。结论认为再次SBRT安全,局部控制率和生存率高于预期。

要点

  • 31例首次SBRT后野内局部复发患者接受再次SBRT,3年总生存率36%、局部控制率53%。
  • 第二次SBRT后放射性肺炎2级4例,未观察到3级放射性肺炎。
  • 4例患者在第二次SBRT后超过5年(63-111个月)无再复发。

核心结论

  • 再次SBRT是安全的;局部控制率和生存率高于预期;SBRT应作为首次局部SBRT后NSCLC或肺转移瘤局部复发的重要治疗选择。

研究设计与样本

  • 本研究为回顾性研究,经本机构伦理委员会批准(2017年9月,批准号27-10)。
  • 纳入31例首次SBRT后野内局部复发的患者,其中NSCLC 23例、肺转移瘤8例。
  • 所有患者首次SBRT后放射性肺炎均为2级或以下。
  • 局部复发的诊断方式:17例经CT和FDG-PET诊断,14例经活检诊断。
  • 首次与第二次SBRT的中位间隔为18个月(范围4-80个月)。

主要发现

  • 全部31例患者3年总生存率为36%,3年局部控制率为53%。
  • 4例患者在第二次SBRT后超过5年(63-111个月)无再复发。
  • 第二次SBRT后放射性肺炎2级4例,未观察到3级放射性肺炎。

关键数值与推荐

  • 首次SBRT剂量按本机构方案主要为48-52 Gy分4次(25例)。
  • 第二次SBRT剂量根据肿瘤大小及与危及器官的距离确定,主要为48-52 Gy分4次(13例)或60 Gy分8次(13例)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study evaluated the safety and efficacy of repeat SBRT for local recurrence of stage I non-small-cell lung cancer (NSCLC) and solitary lung metastasis. METHODS: Thirty-one patients with in-field local relapse of NSCLC (n = 23) or lung metastasis (n = 8) underwent repeat SBRT. All patients had grade 2 or lower radiation pneumonitis after the first SBRT. Local recurrence was diagnosed with CT and FDG-PET in 17 patients and by biopsy in 14. The median interval between the first and second SBRT was 18 months (range, 4-80). The first SBRT dose was mainly 48-52 Gy in 4 fractions (n = 25) according to the institutional protocols. Second SBRT doses were determined based on the tumor size and distance to organs at risk, and were mostly 48-52 Gy in 4 fractions (n = 13) or 60 Gy in 8 fractions (n = 13). RESULTS: At 3 years, overall survival and local control rates were 36 and 53%, respectively, for all 31 patients. Four patients showed no further recurrence for > 5 years (63-111 months) after the second SBRT. Radiation pneumonitis after the second SBRT was grade 2 in 4 patients, and no grade 3 pneumonitis was observed. CONCLUSION: Repeat SBRT was safe. Local control and survival rates were higher than expected. SBRT should be an important treatment option for local recurrence of NSCLC or lung metastasis after previous local SBRT. TRIAL REGISTRATION: This retrospective study was approved by the ethics committee of our institution (September, 2017; approval number: 27-10).

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Ogawa Y, Shibamoto Y, Hashizume C, et al. Repeat stereotactic body radiotherapy (SBRT) for local recurrence of non-small cell lung cancer and lung metastasis after first SBRT. Radiat Oncol. 2018. PMID: 30055636. doi:10.1186/s13014-018-1080-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。